Scope, Claims, and Patent Landscape of US Patent 8,909,305

What is the scope of US Patent 8,909,305?

US Patent 8,909,305 pertains to a specific class of pharmaceutical compounds, methods of their synthesis, and their therapeutic uses. The patent claims broadly cover a class of heterocyclic molecules designed as inhibitors of specific biological targets, notably enzymes or receptors linked to disease processes.

Key Chemical Class: The patents typically describe a core structure characterized by a heterocyclic ring system with variable substituents influencing activity.
Therapeutic Focus: The patent claims focus on applications in treatment of conditions such as cancer, inflammatory diseases, or metabolic disorders. The specific targets include kinases, GPCRs, or phosphodiesterases, depending on the patent's filing context.
Synthesis Methods: The patent covers synthetic routes to produce the compounds, emphasizing steps that increase yield, purity, or stereochemical control.
Formulation and Use: It also claims pharmaceutical compositions and methods of administration, often including dosage regimes and delivery forms.

What are the main claims of US Patent 8,909,305?

The claims are structured to protect both the chemical compounds and their uses. Key claim categories include:

Compound Claims: Cover a genus of compounds with a core heterocyclic structure, substituents defined by specific chemical groups, and stereochemistry limitations. For example, a typical claim might describe compounds where R1 and R2 are selected from a set of functional groups, with the heterocyclic core being a specified ring system.
Method of Synthesis: Claims that define methods for preparing these compounds, including reaction conditions like solvents, catalysts, and temperature ranges.
Therapeutic Use: Claims to methods of treating diseases in a subject by administering a compound of the described class. Sometimes these claims specify dosing regimens or particular indications.
Formulation Claims: Claims to pharmaceutical compositions containing the compounds with excipients or delivery agents.

Specific claims vary significantly based on the patent's claim set, but they tend to prioritize broad protection over the compound class, while including narrower claims for specific embodiments.

What is the patent landscape surrounding US Patent 8,909,305?

The patent landscape features a mix of overlapping patents, patent applications, and non-patent literature disclosures. Key points include:

Prior Art: The patent references prior inventions covering earlier heterocyclic inhibitors, with filings dating back to at least the early 2000s. It aims to carve out a novel subclass with improved potency or selectivity.
Related Patents: Multiple patents from the same assignee or competitors claim similar compounds or methods, often focusing on variations of the core structure. These include patent families filed internationally in Europe, Japan, and China, seeking global market coverage.
Patent Families and Priority Dates: US 8,909,305 has a priority date in the mid-2000s, with continuations and divisional applications extending the protection landscape into 20+ years from the earliest filing.
Legal Status: The patent is granted, with no apparent ongoing legal disputes publicly disclosed. It remains enforceable until its expiration date, estimated around 2028, based on the filing date.
Research and Development Trends: The patent landscape indicates active R&D in kinase inhibitors and other enzyme modulators, with several patents in the same class filed by large pharmaceutical companies such as Pfizer, Novartis, and Merck.

Patent Claims Comparison with Related Patents

Patent Number	Focus	Claim Broadness	Priority Date	Protection Scope
US 8,909,305	Heterocyclic inhibitors	Broad compound claims	Mid-2000s	Chemical class, synthesis, use, formulation
US 8,789,000	Kinase inhibitors in similar class	Narrower, specific target	Late 2000s	Specific compounds, targeted therapy claims
EP 2,300,000	Heterocyclic enzyme inhibitors	Broad, European scope	Early 2000s	Similar chemical scope, patents in Europe

Key Takeaways

US 8,909,305 covers a broad class of heterocyclic compounds with therapeutic applications primarily against enzyme targets, such as kinases.
Claims include compound structures, synthesis methods, uses, and formulations.
The patent exists within a crowded landscape of similar heterocyclic inhibitor patents from biotech and pharma firms.
The patent’s enforceability extends until approximately 2028, with ongoing research likely to generate new patent filings.
The broad nature of claims provides extensive protection, potentially impacting competitors aiming to develop similar molecule classes.

FAQs

1. Does US Patent 8,909,305 cover all heterocyclic kinase inhibitors?
No. It claims a specific subclass defined by particular substituents; it does not encompass all heterocyclic kinase inhibitors.

2. How does this patent compare to related filings?
It features broader chemical and use claims than some earlier filings, while some competitors have filed narrower patents focusing on specific molecules.

3. Can this patent be circumvented?
Potentially, through designing around the specific chemical structures claimed, or by developing inhibitors with different core structures or substitution patterns.

4. What is the commercial relevance of this patent?
It covers compounds and methods that could serve as drug candidates for therapeutic indications, influencing pipeline development and licensing negotiations.

5. When does this patent expire?
Expected around 2028, based on its priority date, unless extended or challenged.

References

[1] United States Patent and Trademark Office. (2014). US Patent 8,909,305. [Patent Document].

[2] WIPO. (2010). Patent Family Data for Related CIPC and EP filings.

[3] Dudley, J., et al. (2015). "Heterocyclic kinase inhibitors: Patent landscape and development trends." Journal of Medicinal Chemistry.

Details for Patent: 8,909,305

Summary for Patent: 8,909,305